In the field of biomedical technology, innovation and successful commercialisation are key indicators of a company’s potential. TekCyte Limited has demonstrated both, with its ground-breaking CYPATCH coating technology recently acquired by Cynata Therapeutics (ASX: CYP). This acquisition was driven by promising clinical trial results and highlights TekCyte’s capacity to develop and deliver impactful medical solutions.
As per the ASX announcement from June 2021, Cynata entered into a worldwide exclusive licence agreement with TekCyte to use this technology. Cynata then agreed to secure outright ownership of the underlying TekCyte technology utilised in CYP-006TK.
The success of CYPATCH
TekCyte’s CYPATCH technology, a proprietary surface modification technique, forms the core of Cynata’s CYP-006TK, a topical wound dressing for diabetic foot ulcers (DFU). This technology allows for the creation of polymer-coated dressings that effectively deliver Mesenchymal Stem Cells (MSCs) to wound sites.
Cynata completed patient enrolment in its DFU trial in April 2024. Interim analysis of the first 16 patients showed a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group, compared to 51.1% in the control group. These promising initial results, as stated by Cynata, led to their decision to acquire the patent family in July 2024.
Cynata has now announced the full data analysis and outcomes. The clinical trial results speak volumes:
- Significant Wound Reduction: After 12 weeks, the CYP-006TK group saw an average wound reduction of 181 mm², while the control group experienced an increase of 355 mm². By 24 weeks, the CYP-006TK group had an average reduction of 261 mm².
- Percentage Improvement: The CYP-006TK group saw a 64.6% improvement in wound size at 12 weeks, compared to a 22% decrease in the control group. At 24 weeks, that improvement jumped to 83.6%.
Notably, the trial indicated that patients with larger wounds experienced even more significant healing with CYP-006TK. This is crucial, as larger wounds often lead to more severe complications, including amputation.
Acquisition of CYPATCH
Cynata’s decision to acquire TekCyte’s CYPATCH technology is a significant endorsement of its value. As Dr. Kilian Kelly, Cynata’s CEO and Managing Director, stated:
“Ownership of this technology strengthens our intellectual property position and simplifies our commercial proposition for potential partners.”
Under the original licensing agreement, this acquisition, valued at $230,000 in Cynata shares, demonstrates Cynata’s confidence in CYPATCH’s potential. It also paves the way for future milestone payments to TekCyte as CYP-006TK meets certain development milestones.
TekCyte’s Ongoing Support and Future Potential
Dr. Tony Simula, TekCyte’s CEO and Managing Director, expressed excitement about Cynata taking ownership of CYPATCH, emphasising the productive collaboration between the two companies.
This collaboration will continue as TekCyte provides ongoing support for the technology’s development, ensuring a smooth transition.
A time for growth
TekCyte has a history of developing and commercialising ground-breaking technologies making it a very compelling investment and corporate partner. The successful clinical trial results, the strategic acquisition by Cynata Therapeutics, and TekCyte’s ongoing industry support highlight the company’s road for future growth.
Potential investors and customers are encouraged to explore TekCyte’s portfolio and learn more about its other innovative solutions.
